J9273 Tisotumab vedodin-tftv - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Tisotumab vedodin-tftv

Brand Name:

Tivdak

Strength:

1mg

HCPCS:

J9273

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Drug Antibody Conjugate

Minor Drug Class:

Tissue factor

Oral (Y/N):

No

FDA Approval Year:

2021

FDA Discontinuation Year:

CMS Effective Date:

March 25, 2022

CMS Discontinuation Date:

Status:

In Use